- Home
- NYC vs MBRX Comparison
NYC vs MBRX Comparison
Compare NYC & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NYC
- MBRX
- Stock Information
- Founded
- NYC 2013
- MBRX 2015
- Country
- NYC United States
- MBRX United States
- Employees
- NYC N/A
- MBRX N/A
- Industry
- NYC Real Estate
- MBRX Biotechnology: Pharmaceutical Preparations
- Sector
- NYC Finance
- MBRX Health Care
- Exchange
- NYC Nasdaq
- MBRX Nasdaq
- Market Cap
- NYC 25.4M
- MBRX 23.5M
- IPO Year
- NYC N/A
- MBRX 2016
- Fundamental
- Price
- NYC $8.05
- MBRX $0.44
- Analyst Decision
- NYC
- MBRX Strong Buy
- Analyst Count
- NYC 0
- MBRX 4
- Target Price
- NYC N/A
- MBRX $5.00
- AVG Volume (30 Days)
- NYC 3.3K
- MBRX 5.2M
- Earning Date
- NYC 11-14-2025
- MBRX 11-12-2025
- Dividend Yield
- NYC N/A
- MBRX N/A
- EPS Growth
- NYC N/A
- MBRX N/A
- EPS
- NYC N/A
- MBRX N/A
- Revenue
- NYC $54,865,000.00
- MBRX N/A
- Revenue This Year
- NYC $8.40
- MBRX N/A
- Revenue Next Year
- NYC $1.62
- MBRX N/A
- P/E Ratio
- NYC N/A
- MBRX N/A
- Revenue Growth
- NYC N/A
- MBRX N/A
- 52 Week Low
- NYC $7.20
- MBRX $0.25
- 52 Week High
- NYC $16.30
- MBRX $3.65
- Technical
- Relative Strength Index (RSI)
- NYC 30.14
- MBRX 42.06
- Support Level
- NYC $7.20
- MBRX $0.46
- Resistance Level
- NYC $8.05
- MBRX $0.51
- Average True Range (ATR)
- NYC 0.39
- MBRX 0.05
- MACD
- NYC -0.12
- MBRX -0.00
- Stochastic Oscillator
- NYC 30.15
- MBRX 4.81
About NYC American Strategic Investment Co.
American Strategic Investment Co is an externally managed company that currently owns a portfolio of commercial real estate located within the five boroughs of New York City, majorly Manhattan. The Company's real estate assets consist of office properties and certain real estate assets that accompany office properties, including retail spaces and amenities.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.